Imatinib resistance in CML

Cancer Letters

Volumn 274, Issue 1, 2009, Pages 1-9

  Volpe, Gisella ^a   Panuzzo, Cristina ^a   Ulisciani, Stefano ^a   Cilloni, Daniela ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Chronic myeloid leukaemia; Imatinib; Imatinib resistance

Indexed keywords

2 [2 METHOXY 5 (2,4,6 TRIMETHOXYSTYRYLSULFONYLMETHYL)ANILINO]PROPIONIC ACID; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 7 [4 [2 (2 METHOXYETHYLAMINO)ETHOXY]PHENYL] 5 (4 METHOXYPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 AMINE; ALPHA INTERFERON; BAG 956; BCR ABL PROTEIN; BOSUTINIB; CD34 ANTIGEN; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DASATINIB; ENZYME INHIBITOR; EVEROLIMUS; IMATINIB; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; NILOTINIB; PHA 739358; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; WT1 PROTEIN; [4 [2 CYCLOPENTYL 9 (3 HYDROXYPHENETHYL)PURIN 6 YLAMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE;

ADVANCED CANCER; ALLELE; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC ACTIVITY; BLAST CELL CRISIS; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CD8+ T LYMPHOCYTE; CHRONIC MYELOID LEUKEMIA; CYTOTOXIC T LYMPHOCYTE; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DRUG BINDING; GENETIC SCREENING; HUMAN; IC 50; IMMUNOGENICITY; IN VITRO STUDY; KARYOTYPE; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DOMAIN; PROTEIN MOTIF; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; SHORT SURVEY;

EID: 57849109399     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.06.003     Document Type: Review

References (64)

1. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., Cornelissen J.J., Fischer T., Hochhaus A., Hughes T., Lechner K., Nielsen J.L., Rousselot P., Reiffers J., Saglio G., Shepherd J., Simonsson B., Gratwohl A., Goldman J.M., Kantarjian H., Taylor K., Verhoef G., Bolton A.E., Capdeville R., and Druker B.J. IRIS Investigators, imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. N. Engl. J. Med. 348 (2003) 994-1004
2. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., Deininger M.W., Silver R.T., Goldman J.M., Stone R.M., Cervantes F., Hochhaus A., Powell B.L., Gabrilove J.L., Rousselot P., Reiffers J., Cornelissen J.J., Hughes T., Agis H., Fischer T., Verhoef G., Shepherd J., Saglio G., Gratwohl A., Nielsen J.L., Radich J.P., Simonsson B., Taylor K., Baccarani M., So C., Letvak L., and Larson R.A. Five-year follow-up of patients receiving imatinib for chronic myeloid leukaemia. N. Engl. J. Med. (2006) 355 2408-2417
3. Apperley J.F. Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 8 (2007) 1018-1029
4. Cortes J., and O'Dwyer M.E. Clonal evolution in chronic myelogenous leukaemia. Hematol. Oncol. Clin. North Am. 18 (2004) 671-684
5. Kreil S., Pfirrmann M., Haferlach C., et al. German Chronic Myelogenous Leukemia (CML) Study Group. Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. Blood 110 (2007) 1283-1290
6. Deutsch E., Dugray A., AbdulKarim B., Marangoni E., Maggiorella L., Vaganay S., M'Kacher R., Rasy S.D., Eschwege F., Vainchenker W., Turhan A.G., and Bourhis J. BCR-ABL down-regulates the DNA repair protein DNA-PKcs. Blood 97 (2001) 2084-2090
7. Deutsch E., Jarrousse S., Buet D., Dugray A., Bonnet M.L., Vozenin-Brotons M.C., Guilhot F., Turhan A.G., Feunteun J., and Bourhis J. Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells. Blood 101 (2003) 4583-4588
8. Janssen J.J., Klaver S.M., Waisfisz Q., Pasterkamp G., de Kleijn D.P., Schuurhuis G.J., and Ossenkoppele G.J. Identification of genes potentially involved in disease transformation of CML. Leukemia 19 (2005) 998-1004
9. Johansson B., Fioretos T., and Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukaemia. Acta Haematol. 107 (2002) 76-94
10. Donato N.J., Wu J.Y., Stapley J., Gallick G., Lin H., Arlinghaus R., and Talpaz M. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101 (2003) 690-698
11. White D.L., Saunders V.A., Dang P., Engler Venables J.A., Zrim S., Zannettino A., Lynch K., Manley P.W., and Hughes T. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 110 (2007) 4064-4072
12. Al Ali H.K., Heinrich M.C., Lange T., Krahl R., Mueller M., Muller C., Niederwieser D., Druker B.J., and Deininger M.W. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol. J. 5 (2004) 55-60
13. Soverini S., Colarossi S., Gnani A., Rosti G., Castagnetti F., Poerio A., Iacobucci I., Amabile M., Abruzzese E., Orlandi E., Radaelli F., Ciccone F., Tiribelli M., di Lorenzo R., Caracciolo C., Izzo B., Pane F., Saglio G., Baccarani M., and Martinelli G. GIMEMA Working Party on Chronic Myeloid Leukemia, contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin. Cancer Res. 12 (2006) 7374-7379
14. Weisberg E., Manley P.W., Cowan-Jacob S.W., Hochhaus A., and Griffin J.D. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat. Rev. Cancer 7 (2007) 345-356
15. Branford S., Rudzki Z., Walsh S., Parkinson I., Grigg A., Szer J., Taylor K., Herrmann R., Seymour J.F., Arthur C., Joske D., Lynch K., and Hughes T. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102 (2003) 276-283
16. Soverini S., Martinelli G., Rosti G., Bassi S., Amabile M., Poerio A., Giannini B., Trabacchi E., Castagnetti F., Testoni N., Luatti S., de Vivo A., Cilloni D., Izzo B., Fava M., Abruzzese E., Alberti D., Pane F., Saglio G., and Baccarani M. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J. Clin. Oncol. 23 (2005) 4100-4109
17. Jabbour E., Kantarjian H., Jones D., Talpaz M., Bekele N., O'Brien S., Zhou X., Luthra R., Garcia-Manero G., Giles F., Rios M.B., Verstovsek S., and Cortes J. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20 (2006) 1767-1773
18. Liu W.H., and Makrigiorgos G.M. Sensitive and quantitative detection of mutations associated with clinical resistance to STI-571. Leuk. Res. 27 (2003) 979-982
19. Roche-Lestienne C., Soenen-Cornu V., Grardel-Duflos N., Lai J.L., Philippe N., Facon T., Fenaux P., and Preudhomme C. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100 (2002) 1014-1018
20. Kreuzer K.A., Le Coutre P., Landt O., Na I.K., Schwarz M., Schultheis K., Hochhaus A., and Dörken B. Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique. Ann. Hematol. 82 (2003) 284-289
21. Willis S.G., Lange T., Demehri S., Otto S., Crossman L., Niederwieser D., Stoffregen E.P., McWeeney S., Kovacs I., Park B., Druker B.J., and Deininger M.W. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 106 (2005) 2128-2137
22. Deininger M.W., McGreevey L., Willis S., Bainbridge T.M., Druker B.J., and Heinrich M.C. Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography. Leukemia 18 (2004) 864-871
23. Soverini S., Martinelli G., Amabile M., Poerio A., Bianchini M., Rosti G., Pane F., Saglio G., and Baccarani M. Italian Cooperative Study Group on Chronic Myeloid Leukemia; European LeukemiaNet-6th Framework Program of the European Community, denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. Clin. Chem. 50 (2004) 1205-1213
24. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J., and Sawyers C.L. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2 (2002) 117-125
25. Branford S., Rudzki Z., Walsh S., Grigg A., Arthur C., Taylor K., Herrmann R., Lynch K.P., and Hughes T.P. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99 (2002) 3472-3475
26. Khorashad J.S., Anand M., Marin D., Saunders S., Al Jabary T., Iqbal A., Margerison S., Melo J.V., Goldman J.M., Apperley J.F., and Kaeda J. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia 20 (2006) 658-663
27. Baccarani M., Saglio G., Goldman J.M., Hochhaus A., Simonsson B., Appelbaum E., Apperley J.F., Cervantes F., Cortes J., Deininger M.W., Gratwohl A., Guilhot F., Horowitz M., Hughes T., Kantarjian H., Larson R.A., Niederwieser D., Silver R.T., and Hehlmann R. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European Leukemia Net. Blood 108 (2006) 1809-1820
28. Hughes T., Deininger M.W., Hochhaus A., Branford S., Radich J., Kaeda J., Baccarani M., Cortes J., Cross N.C., Druker B.J., Gabert J., Grimwade D., Hehlmann R., Kamel- Reid S., Lipton J., Longtine J., Martinelli G., Saglio G., Soverini S., Stock W., and Goldman J.M. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors - review and recommendations for 'harmonizing' current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108 (2006) 28-37
29. Hughes T., and Branford S. Monitoring disease response. In: Melo J.V., and Goldman J.M. (Eds). Myeloproliferative Disorders (2007), Springer-Verlag, Berlin, Heidelberg 143-164
30. Branford S., Cross N.C., Hochhaus A., Radich J., Saglio G., Kaeda J., Goldman J., and Hughes T. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia 20 (2006) 1925-1930
31. Hughes T.P., Kaeda J., Branford S., Rudzki Z., Hochhaus A., Hensley M.L., Gathmann I., Bolton A.E., van Hoomissen I.C., Goldman J.M., and Radich J.P. International Randomised Study of Interferon versus STI571 (IRIS) Study Group, frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukaemia. N. Engl. J. Med. 349 (2003) 1423-1432
32. Rousselot P., Huguet F., Rea D., Legros L., Cayuela J.M., Maarek O., Blanchet O., Marit G., Gluckman E., Reiffers J., Gardembas M., and Mahon F.X. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109 (2007) 58-60
33. Branford S., Rudzki Z., Parkinson I., Grigg A., Taylor K., Seymour J.F., Durrant S., Browett P., Schwarer A.P., Arthur C., Catalano J., Leahy M.F., Filshie R., Bradstock K., Herrmann R., Joske D., Lynch K., and Hughes T. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 104 (2004) 2926-2932
34. Wang L., Knight K., Lucas C., and Clark R.E. The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukaemia. Haematologica 9 (2006) 1235-1239
35. Marin D., Kaeda J., Szydlo R., Saunders S., Fleming A., Howard J., Andreasson C., Bua M., Olavarria E., Rahemtulla A., Dazzi F., Kanfer E., Goldman J.M., and Apperley J.F. Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse. Leukemia 19 (2005) 507-512
36. Michor F., Hughes T.P., Iwasa Y., Branford S., Shah N.P., Sawyers C.L., and Nowak M.A. Dynamics of chronic myeloid leukaemia. Nature 435 (2005) 1267-1270
37. Elrick L.J., Jorgensen H.G., Mountford J.C., and Holyoake T.L. Punish the parent not the progeny. Blood 105 (2005) 1862-1866
38. Copland M., Hamilton A., Elrick L.J., Baird J.W., Allan E.K., Jordanides N., Barow M., Mountford J.C., and Holyoake T.L. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107 (2006) 4532-4539
39. La Rosée P., Shen L., Stoffregen E.P., Deininger M., and Druker B.J. No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec/Glivec). Hematol. J. 4 (2003) 413-419
40. Jiang X., Zhao Y., Chan W.Y., Pang E., Eaves A., and Eaves C. Leukemic stem cells of chronic phase CML patients consistently display very high BCR-ABL transcript levels and reduced responsiveness to imatinib mesylate in addition to generating a rare subset that produce imatinib mesylate-resistant differentiated progeny. Blood 104 (2004) 711
41. + cells from chronic myelogenous leukaemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 105 (2005) 2093-2098
42. + cells by the histone deacetylase inhibitor LAQ824 in combination with imatinib. Blood 110 (2007) 1031
43. Copland M., Pellicano F., Richmond L., Allan E.K., Hamilton A., Lee F.Y., Weinmann R., and Holyoake T.L. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergises with tyrosine kinase inhibitors. Blood 111 (2008) 2843-2853
44. Hochhaus A., Kantarjian H.M., Baccarani M., Lipton J.H., Apperley J.F., Druker B.J., Facon T., Goldberg S.L., Cervantes F., Niederwieser D., Silver R.T., Stone R.M., Hughes T.P., Muller M.C., Ezzeddine R., Countouriotis A.M., and Shah N.P. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109 (2007) 2303-2309
45. Kantarjian H.M., Giles F., Gattermann N., Bhalla K., Alimena G., Palandri F., Ossenkoppele G.J., Nicolini F.E., O'Brien S.G., Litzow M., Bhatia R., Cervantes F., Haque A., Shou Y., Resta D.J., Weitzman A., Hochhaus A., and le Coutre P. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and Intolerance. Blood 110 (2007) 3540-3546
46. Soverini S., Gnani A., Colarossi S., Castagnetti F., Palandri F., Giannoulia P., Paolini S., Abruzzese E., Merante S., Rondoni M., Iacobucci I., Poerio A., Rosti G., Baccarani M., and Martinelli G. Philadelphia chromosome-positive leukemia patients who harbor imatinib-resistant mutations have a higher likelihood of developing additional mutations associated with resistance to novel tyrosine kinase inhibitors. Blood 110 (2007) 322
47. Shah N.P., Skaggs B.J., Branford S., Hughes T.P., Nicoll J.M., Paquette R.L., and Sawyers C.L. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J. Clin. Invest. 117 (2007) 2562-2569
48. Cortes J., Bruemmendorf T., Kantarjian H., Khoury J., Rosti G., Fischer T., Tornaghi L., Hewes B., Martin E.C., and Gambacorti-Passerini C. Efficacy and safety of bosutinib (SKI-606) among patients with chronic phase Ph+ chronic myelogenous leukemia (CML). Blood 110 (2007) 733
49. Jorgensen H.G., Allan E.K., Graham S.M., Godden J.L., Richmond L., Elliott M.A., Mountford J.C., Eaves C.J., and Holyoake T.L. Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia 19 (2005) 1184-1191
50. Dengler J., von Bubnoff N., Decker T., Peschel C., and Duyster J. Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl positive cells with moderate resistance to imatinib. Leukemia 19 (2005) 1835-1838
51. Sillaber C., Mayerhofer M., Böhm A., Vales A., Gruze A., Aichberger K.J., Esterbauer H., Pfeilstöcker M., Sperr W.R., Pickl W.F., Haas O.A., and Valent P. Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. Eur. J. Clin. Invest. 38 (2008) 43-52
52. E. Weisberg, L. Banerji, R.D. Wright, R. Barrett, A. Ray, D. Moreno, L. Catley, J. Jiang, E. Hall-Meyers, M. Sauveur-Michel, R. Stone, I. Galinsky, E. Fox, A.L. Kung, J.D. Griffin, Potentiation of anti-leukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells, Blood (2008), January 9 [Epub ahead of print] DOI 10.1182/blood-2007-09-114454.
53. Gu J.J., Santiago L., and Mitchell B.S. Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl. Blood 105 (2005) 3270-3277
54. Lim S.H., and Coleman S. Chronic myeloid leukemia as an immunological target. Am. J. Hematol. 54 (1997) 61-67
55. Pinilla-Ibarz J., Cathcart K., and Scheinberg D.A. CML vaccines as a paradigm of the specific immunotherapy of cancer. Blood Rev. 14 (2000) 111-120
56. Cathcart K., Pinilla-Ibarz J., Korontsvit T., Schwartz J., Zakhaleva V., Papadopoulos E.B., and Scheinberg D.A. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukaemia. Blood 103 (2004) 1037-1042
57. Bocchia M., Gentili S., Abruzzese E., Fanelli A., Iuliano F., Tabilio A., Amabile M., Forconi F., Gozzetti A., Raspadori D., Amadori S., and Lauria F. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 365 (2005) 657-662
58. Molldrem J.J., Lee P.P., Wang C., Felio K., Kantarjian H.M., Champlin R.E., and Davis M.M. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukaemia. Nat. Med. 6 (2000) 1018-1023
59. Qazilbash H.M., Wieder E.D., Thall P.F., Wang X., Rios R.L., Lu S., Kant S., Giralt S., Estey E.H., Cortes J., Komanduri K., Champlin R.E., and Molldrem J.J. PR1 peptide vaccine-induced immune response is associated with better event-free survival in patients with myeloid leukemia. Blood 110 (2007) 283
60. Rezvani K., Price D.A., Brenchley J.M., Kilical Y., Gostick E., Sconocchia G., Hansmann K., Kurlander R., Douek D.C., and Barrett A.J. Transfer of PR1-specific T-cell clones from donor to recipient by stem cell transplantation and association with GvL activity. Cytotherapy 9 (2007) 245-251
61. Rezvani K., Yong A.S.M., Mielke S., Savani B.N., Musse L., Superata J., Jafarpour B., Boss C., and Barrett A.J. Leukemia-associated antigen specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 110 (2007) 287
62. Li Z., Qiao Y., Liu B., Laska E.J., Chakravarthi P., Kulko J.M., Bona R.D., Fang M., Hegde U., Moyo V., Tannenbaum S.H., Ménoret A., Gaffney J., Glynn L., Runowicz C.D., and Srivastava P.K. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukaemia. Clin. Cancer Res. 11 (2005) 4460-4468
63. Srivastava P.K., and Amato R.J. Heat shock proteins: the 'Swiss Army Knife' vaccines against cancers and infectious agents. Vaccine 19 (2001) 2590-2597
64. Volpe G., Cignetti A., Panuzzo C., Kuka M., Vitaggio K., Brancaccio M., Perrone G., Rinaldi M., Prato G., Fava M., Geuna M., Pautasso M., Casnici C., Signori E., Tonon G., Tarone G., Marelli O., Fazio V.M., and Saglio G. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches. Cancer Res. 67 (2007) 5300-5307